Entrada Therapeutics provided an update on its financial position and pipeline progress for the third quarter ended September 30, 2024. The company reported cash, cash equivalents, and marketable securities of $449.3 million as of September 30, 2024. This robust cash position is expected to support the company's ongoing operations and clinical development efforts.
The company confirmed it is on track to submit global regulatory filings for planned Phase 2 clinical trials for both ENTR-601-44 and ENTR-601-45 in the fourth quarter of 2024. Additionally, Vertex Pharmaceuticals announced the completion of the single ascending dose (SAD) and the initiation of the multiple ascending dose (MAD) portions of its global Phase 1/2 clinical trial for the partnered VX-670 program.
These updates follow the presentation of additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for Duchenne muscular dystrophy (DMD) at the 2024 World Muscle Society Annual Congress. The continued advancement of these programs underscores Entrada's commitment to its Duchenne franchise and strategic partnerships.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.